Alexander Semenov took part in a visiting meeting of the RSPP in Saransk
On October 5, the President of the Acticomp, Alexander Semenov, took part in a visiting meeting of several RSPP Commissions in Saransk on the topic “Current problems of the pharmaceutical industry. Achieving technological sovereignty in providing healthcare with medicines through the development of domestic production of small-scale chemical products.”
The following addressed the audience with welcoming remarks: President of the RSPP Alexander Shokhin, President of the Russian Chamber of Commerce and Industry Sergei Katyrin, and Head of the Republic of Mordovia Artyom Zdunov.
Chairman of the Board of Directors Pyotr Bely spoke about the experience of the Promomed Group of Companies in developing the production of full-cycle medicines.
Next, the meeting participants reviewed the action plan for the implementation of the Pharma-2030 strategy, which was presented by Dmitry Galkin, Director of the Department for Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of the Russian Federation, and Viktor Dmitriev, General Director of the ARPP.
Alexander Semenov’s speech was dedicated to the state and prospects for the development of the pharmaceutical substances market in Russia. He emphasized the importance for the industry of such events within the framework of the Pharma-2030 strategy, such as the “second wheel” program and the introduction of a traceability system for pharmaceutical substances. However, these measures to support domestic API manufacturers may not be enough to achieve complete import independence. In this regard, it is also important to think about tax preferences for manufacturers for an investment period of +3 years, preferential credit programs for full-cycle manufacturers, as well as subsidies for companies that build local production facilities and produce in-demand APIs. It is also necessary to update the list of pharmaceutical drugs: exclude commercial items from it and add the drugs that are most in demand from a therapeutic point of view. In his report, Alexander Semyonov also identified factors that negatively affect the development of the Russian pharmaceutical industry - these are export duties, the possible introduction of excise taxes on the API “Ethyl Alcohol”, as well as the lack of restrictions on the registration by foreign manufacturers of generics not localized in the Russian Federation.
Irina Vendilo, vice-president of the Russian Union of Chemists, spoke about the development of production of small-scale chemical products for the production of medicines.
The participants also discussed improving the legal regulation of the circulation of medicines.
In the afternoon, the participants of the on-site meeting visited the production sites of Biokhimik JSC of the Promomed group - enterprises with a full production cycle, from the molecule to the finished dosage form.